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Milrinone is an inotropic drug with vasodilator activity that has been shown to 
be useful in increasing cardiac output and decreasing wedge pressure. Despite 
these advantages, it is unknown whether this drug can be used for the 
treatment of perioperative spasm of coronary bypass grafts. This study was 
undertaken to investigate the in vitro vascular effect of milrinone on internal 
thoracic arteries obtained from patients under'going coronary artery bypass 
grafting. The results howed that miMnone produced a potent, concentration- 
dependent, preventive ffect on the norepinephrine-induced contraction of 
internal thoracic arteries, a  well as reversing contraction of internal thoracic 
arteries by receptor-dependent agents, including the thromboxane A2mimetic 
U46619, the vasoconstrictor peptide ndothelin-1, and the al-adrenal receptor 
agonist phenylephrine. The relaxing effect of milrinone was weaker, however, 
on internal thoracic arteries contracted with 25 mmol/L potassium chloride. 
Comparison of milrinone with other vasodilators, including papaverine, nitro- 
prusside, and glyceryl trinitrate, showed milrinone to be more potent han 
papaverine but less potent than nitroprusside and glyceryl trinitrute. The 
inhibitory effect of milrinone on internal thoracic artery contraction appeared 
as a reduction in contractile force, not as an increase in the values of 
concentrations of the agonists causing 50% maximal contraction, which 
indicates that milrinone exerts its vasodilator effect directly on the smooth 
muscles, not on the membrane r ceptors. The results also showed no signifi- 
cant difference in relaxing effect between i ternal thoracic artery rings with and 
without endothelium. In conclusion, this study provides experimental evidence 
that milrinone is a potent, endothelium-independent, dir c  vasodilator of the 
human internal thoracic artery and provides the scientific rationale for a 
future clinical trial with this drug for the perioperative treatment of internal 
thoracic artery spasm in cardiac surgical patients. (J Thorac Cardiovasc Surg 
1997;113:108-13) 
M ilrinone, a phosphodiesterase inhibitor, is a 
noncatecholamine, nonglycosidic inotropic 
agent with vasodilator activity. 1This combination of 
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positive inotropic and vasodilator activity has been 
shown to be beneficial in increasing cardiac output 
and decreasing left ventricular end-diastolic pres- 
sure, pulmonary wedge pressure, right atrial pres- 
sure, and systemic vascular resistance in patients 
with severe congestive heart failure. 2'3 It is well 
tolerated.: Despite these advantages, it is unknown 
whether this drug can be used for the treatment of 
perioperative spasm of coronary artery bypass 
grafts. 
In addition, fewer data are available concerning 
direct vasodilator activity of milrinone than on its 
cardiotonic effect. It is important to understand the 
vasoactivity of this drug on the bypass grafts before 
it is used clinically. 
Internal thoracic artery (ITA) grafts have greater 
late patency and longevity than do saphenous vein 
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grafts.4, s ITA  is also more resistant o the develop- 
ment of atherosclerosis than are the native coronary 
arteries. 6 ITA  spasm may contribute to early myo- 
cardial ischemia, however, increasing perioperative 
morbidity and mortal i ty] '  s This spasm may be 
caused by injury of the endothel ium of the ITA  
during surgical procedure and by drugs adminis- 
tered systemically to support the circulation. Pre- 
vention and treatment of ITA  spasm by vasodilator 
drugs are important issues in coronary artery bypass 
grafting. Milrinone has both cardiotonic and vaso- 
dilator activities. The use  of milrinone to treat 
perioperative patients may be beneficial in the pre- 
vention of ITA  spasm and in the recovery of cardiac 
function. This study was undertaken to investigate 
the in vitro effect of milrinone on the human ITA  to 
obtain scientific evidence before the clinical appli- 
cation. 
Methods 
Preparation of vessels. Preparation of vessels was un- 
dertaken as described elsewhere. 9-11 Briefly, human ITA 
graft segments were taken from patients undergoing cor- 
onary artery bypass grafting. The distal segments (but far 
before the branch points) were collected, cleaned of 
connective tissues, and cut into 3 mm long rings. In some 
rings the endothelium was removed gently by forceps. The 
rings were suspended on wire hooks in organ chambers 
containing Krebs' solution with the following composition: 
sodium ion, 144 retool/L; potassium ion, 5.9 retool/L; cal- 
cium ion, 2.5 mmol/L; magnesium ion, 1.2 retool/L; chlo- 
ride ion, 128.7 retool/L; bicarbonate ion, 25 mmol/L; 
sulfate ion, 1.2; phosphate ion, 1.2 mmol/L; and glucose, 
11 mmol/L. The solution was aerated with a gas mixture of 
95% oxygen and 5% carbon dioxide at 37 ° +_ 0.1 ° C. After 
the rings were equilibrated without tension on the wire 
hooks for 1 hour, a normalizing procedure was performed. 
The resting tension applied to each ring was equivalent to 
that required to stretch the ring to 90% of its internal 
circumference when distended with a transmural pressure 
of 100 mm Hg. In this study, the average force of the 
resting tension was 4.06 +_ 0.27 g. A computer system was 
used to monitor the organ chamber experiments. The 
maximal contractile response was obtained with 3 × 10 -6  
mol/L norepinephrine. The presence or absence of func- 
tional endothelium was tested by the r sponse to acetyl- 
choline (3 × 10 .6 mol/L) in rings precontracted with 
norepinephrine (3 × 10-7). Mean curves were obtained 
from at least six different ITA rings from six different 
patients. Each ring was used to obtain the concentration- 
response curve for only one tested agent, but relevant 
agents and different concentrations were tested at the 
same time with separate artery rings from the same 
patient. 
Data analysis. The effective concentration f a contrac- 
tile or relaxing agent that caused 50% of maximal con- 
tractile force or relaxation (ECs0) and the maximal re- 
sponse induced by a constrictor (Max) were determined 
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Fig. 1. Graphs showing preventive ffect of milrinone on 
contraction of human ITAs induced by norepinephrine 
(noradrenaline). Mean concentration-contraction curves 
for norepinephrine w re obtained when 10 -7  mol/L, 10 6 
tool/L, or 10 -s mol/L milrinone was added 15 minutes 
before starting norepinephrine curves. Percentage of max- 
imal contraction is defined as percentage of maximal 
response to 3 × 10 6 mol/L norepinephrine. Values of 
ECso and Max are shown in the text. Values for each dose 
in the figure are mean _+ SEM (n = 6). Asterisks denote 
significant differences versus control (*p < 0.05, **p < 
0.01). Milrinone reduced norepinephrine-induced con- 
traction in a dose-dependent manner. 
from each curve by a logistic, curve-fitting program called 
FLEXIFIT. 12 Statistical significance was determined by 
an unpaired Student's t test for two-group comparisons 
and a two-way analysis of variance for multiple-group 
comparisons. Values are mean values (_+ standard error 
of the mean [SEM]). Significance was taken at p values 
lower than 0.05. 
Drugs and chemicals. Milrinone (1,6-dihydro-2-metfi- 
yl-6-oxo-[3,4'-bipyridine]-5-carbonitrile) was provided by 
Sterling-Winthrop (Rensselaer, N.Y.). U46619 (9,11- 
dideoxy-lla,9a-epoxymethano-prostaglandin F2~ ) was a 
gift from The Upjohn Company (Kalamazoo, Mich.). 
Endothelin-1 (ET-1) was purchased from American Pep- 
tide Company (Sunnyvale, Calif.). Papaverine, nitroprus- 
side, and glyceryl trinitrate were purchased from David 
Bull Laboratories (Melbourne, Australia). All other drugs 
and chemicals were purchased from Sigma Chemical Co. 
(St. Louis, Mo.). 
Results 
Prevention of ITA contraction. A 15-minute pre- 
treatment of  the ITA  rings with increasing con- 
centrations (10 -7 to 10 -5 mol/L) of milrinone 
significantly prevented norepinephrine-induced 
contraction in a concentrat ion-dependent manner 
(Fig. 1). Values of ECs0 were as follows: 6.82 + 0.11 
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Fig. 2. Graphs showing reversal by milrinone of precon- 
traction of human ITAs by various agents. ITA rings were 
precontracted with the thromboxane A 2 mimetic U46619 
(10 -8 mol/L), the vasoconstrictor peptide ET-1 (3 × 10 -9 
tool/L), the al-adrenal receptor agonist phenylephrine 
(3 × 10 -7 tool/L), or 25 mmol/L potassium chloride, 
followed by the addition of increasing concentrations of 
milrinone (1 × 10 -9 mol/L to 1 x 10 .4 tool/L). Values of 
ECso are shown in text. Values for each dose in figure are 
mean + SEM (n = 6). Asterisks denote significant differ- 
ences versus control *p < 0.05, **p < 0.01). Difference 
between milrinone's effect on potassium-induced contrac- 
tion and its effect on contraction i duced by receptor- 
dependent vasoconstrictors was significant. There were no 
significant differences among receptor-dependent vaso- 
constrictors. 
- log mol/L for the control group and 6.92 + 0.13 
- log tool/L, 6.73 _+ 0.12 - log tool/L, and 6.73 _+ 
0.10 - log mol/L for groups treated with 10 -7 tool/L, 
10 .6 mol/L, and 10 .5 mol/L milrinone, respectively. 
There were no significant differences in the values of 
ECs0 between the control group and each treatment 
group, nor among different reatment groups. Val- 
ues of Max were as follows: 100.1% +_ 1.5% for the 
control group and 80.9% +_ 4.7%, 53.3% + 3.2%, 
and 19.9% _+ 2.1% for the groups treated with 10 -7 
mol/L, 10 .6 tool/L, and 10 .5 mol/L milrinone, re- 
spectively. Milrinone significantly reduced the val- 
ues of Max ~ < 0.05 for 10 -7 mol/L vs control, p < 
0.01 for 10 .6 mol/L vs control, andp < 0.01 for 10 .5 
mol/L vs control). The significance l vels of compar- 
isons for each dose are shown in Fig. 1. 
Reversal of ITA contraction. The ITA rings were 
contracted with the thromboxane A 2 mimetic 
U46619 (10 -s mol/L), the vasoconstrictive p ptide 
ET-1 (3 × 10 -9 tool/L), the al-adrenal receptor 
agonist phenylephrine (3 × 10 -7 mol/L), or 25 
mmol/L potassium chloride. These concentrations 
of agents caused contraction of ITAs by about 80% 
in our previous tudies (laboratorial data). The rings 
were then relaxed by the addition of increasing 
concentrations of milrinone (10 .9 mol/L to 10 -4 
mol/L). The results howed that milrinone produced 
concentration-dependent relaxation of the ITA 
rings precontracted byeach of the agents used (Fig. 
2). There was no significant difference in potency of 
milrinone among the rings precontracted with 
U46619, ET-1, and phenylephrine, which had ECs0 
values of 6.14 + 0.16 - log  mol/L, 6.23 + 0.28 - log 
tool/L, and 5.98 +_ 0.17 - log tool/L, respectively 
(p > 0.05, n = 6). However, milrinone was weaker in 
the relaxation of rings precontracted with potassium 
chloride (ECs0 4.84 + 0.12 - log  mol/L,p < 0.01 vs 
each receptor-dependent agent, n = 6). The signif- 
icance of comparisons at each dose is shown in Fig. 
2. 
Relaxing effect of milrinone on rings with or 
without endothelium. There was no significant dif- 
ference in the relaxing effect of milrinone between 
rings with (Fig. 3, A) and without (Fig. 3, B) 
endothelium. Similar results were obtained from six 
separate experiments (p > 0.05). 
Comparisons of milrinone with other vasodila- 
tors. The ITA rings were contracted with 10 .8 
mol/L U46619 and then relaxed in separate trials by 
increasing concentrations of milrinone, papaverine, 
nitroprusside, and glyceryl trinitrate. The results 
(Fig. 4) show that the relaxing effect of milrinone 
was stronger than that of papaverine, with an ECs0 
of 6.14 _+ 0.16 - log mol/L versus 5.30 _+ 0.13 - log  
mol/L (p < 0.01, n = 6), and weaker than those of 
nitroprusside (7.1 + 0.26 - log mol/L) and glyceryl 
trinitrate (7.0 +_ 0.25 - log  mol/L;p < 0.01 for all vs 
milrinone, n = 6). The significance of comparisons 
at each dose is shown in Fig. 4. There was no 
significant difference between nitroprusside and 
glyceryl trinitrate in either ECs0 or each dose. 
Discussion 
This study demonstrates that the cardiotonic drug 
milrinone produces a potent, concentration-depen- 
dent, inhibitory effect on ITA contraction. It also 
exerts a relaxing effect on ITAs contracted with 
receptor-dependent agents. The mechanisms are 
not dependent on endothelium. The potency of 
milrinone is higher than that of papaverine and 
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Fig. 3. Graphs showing lack of involvement of endothe- 
lium in milrinone-induced relaxation of human ITAs. ITA 
rings with (+EC) or without (-EC) endothelium were 
precontracted with the thromboxane A 2 mimetic U46619 
(10 -s mol/L), followed by the addition of increasing 
concentrations of milrinone (1 × 10 .9 mol/L to 1 × 10 -4  
mol/L). Original traces are representative of six separate 
experiments. There was no significant difference in relax- 
ing effects of milrinone on rings with and without endo- 
thelium (p > 0.05). EC, Endothelium. 
lower than those of nitroprusside and glyceryl trini- 
trate. 
Selection of potassium chloride, U46619, ET-1, 
and phenylephrine as contracting agents in this 
study was made on the basis of the belief that 
intracellular free calcium (for contraction) will be 
raised by (1) a calcium ion influx through voltage- 
operated channels in response to membrane depo- 
larization or (2) a release of calcium ion into the 
cytoplasm from bound intracellular calcium stores 
or from extracellular stores, triggered by receptors 
activated on the membrane (receptor-operated 
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Fig. 4. Graphs showing comparison of milrinone with 
other vasodilators. ITA rings were precontracted with the 
thromboxane Az mimetic U46619 (10 -s tool/L), followed 
by addition of increasing concentrations (1 × 10 -9 mol/L 
to 1 × 10 4 mol/L) of milrinone, papaverine, nitroprus- 
side, and glyceryl trinitrate. Values of ECso are given in 
text. Values for all doses in figure are mean + SEM (n = 
6). Asterisks and plus signs denote significant differences 
versus control (*p < 0.05, +p < 0.05, **p < 0.01, ++p < 
0.01). Relaxing effect of milrinone was significantly stron- 
ger than that of papaverine (*) but significantly weaker 
than those of nitroprusside and glyceryl trinitrate (+). 
There were no significant differences between itroprus- 
side and glyceryl trinitrate. 
channels). Similar to the previous studies, 9 potas- 
sium ion served in this study as a membrane depo- 
larizing agent to open voltage-operated channels. 
The other agonists were employed as receptor- 
dependent agents to open receptor-operated chan- 
nels, In this study, it was clearly shown that milri- 
none is highly effective in vitro in the inhibition of 
the contraction associated with receptor-operated 
channels but is weaker in inhibition of the contrac- 
tion associated with voltage-operated channels. It is 
known that most vasoconstrictors in human body 
are receptor dependent, and the high (25 mmol/L) 
potassium ion concentration used in the study as a 
pharmacologic evaluation approach is above normal 
values of potassium ion in human plasma. The weak 
effect of milrinone on contraction induced by 25 
mmol/L potassium is therefore of limited clinical 
relevance. 
The inhibitory effect of milrinone on ITA contrac- 
tion appeared only as a reduction in the values of 
Max, not as an increase in ECs0. These results 
indicate that the vasodilator effect of milrinone is 
exerted directly on the smooth muscles or by non- 
1 1 2 Liu et al. 
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competitive inhibition of the membrane receptors. 
If the effect of milrinone were achieved by compet- 
itive blocking of norepinephrine receptors, ECs0 
would have increased and Max would have not 
changed. 
Milrinone is an inhibitor of the cyclic guanosine 
monophospate-inhibited phosphodiesterase III. 13 It 
results in an increase in cyclic adenosine monophos- 
phate levels. 1' 13 Studies have shown that the time 
course for this increase does not seem to correspond 
to the increase in muscle-developed tension, ~ how- 
ever, suggesting that it is unlikely to be the only 
mechanism responsible for the effect of the drug. 
Endothelium-dependent mechanisms were there- 
fore tested in this study. Endothelium-dependent 
relaxation is achieved by a combination of endothe- 
lium-derived prostacyclin, itric oxide, and endothe- 
lium-dependent hyperpolarizing factor. The results 
of this study showed no significant difference in the 
relaxing effect of milrinone with and without endo- 
thelium. This indicates that the endothelium-depen- 
dent mechanisms are not involved in the vasodilator 
effect of milrinone. Because the vasodilator effect is 
independent of endothelium, milrinone may be use- 
ful in the treatment of spasm arising from endothe- 
lial dysfunction caused by surgical procedure, ath- 
erosclerosis, or drugs. 
In this study, milrinone was more potent than 
papaverine, a vasodilator commonly used for prep- 
aration of ITAs during coronary artery bypass graft- 
ing. Papaverine is usually used at high concentra- 
tion, and its solution is acidic. Whether milrinone 
can be used to replace papaverine for the prepara- 
tion of ITAs during coronary artery bypass grafting 
awaits further clinical investigation. Although milri- 
none was less potent han nitroprusside and glyceryl 
trinitrate, it is well known that the latter two agents 
have some disadvantages. It may be difficult to 
control their rapid, strong, and short effects. Glyc- 
eryl trinitrate is associated with tachyphylaxis to its 
vasodilator effect. Both nitroprusside and glyceryl 
trinitrate are pure vasodilators and often require 
combination with other drugs, leading to use of 
multiple drugs. Milrinone has several theoretic ad- 
vantages as an inotropic agent. In particular, it is a 
direct vasodilator, does not increase myocardial 
oxygen consumption, and is well tolerated. In addi- 
tion, there are no reports of tachyphylaxis during the 
use of milrinone. Milrinone thus has the potential to 
be a superior drug for the perioperative treatment 
of cardiac patients. 
Application of the results from in vitro studies to 
the clinical situation requires caution. This study 
does not provide direct clinical data for application 
of milrinone. The experimental data do, however, 
provide a scientific basis for a future clinical trial 
with this drug to prevent and to treat perioperative 
spasm of coronary artery bypass grafts. The concen- 
trations used in the laboratory study cannot be 
directly translated to clinical dosages because con- 
ditions in vitro are significantly different from those 
in vivo. Bailey and colleagues, 14in their report of a 
pharmacokinetic study on milrinone in cardiac pa- 
tients, demonstrated that a milrinone dose of 50 
/xg/kg at an infusion rate of 0.5/xg × kg -1 × rain -1 
consistently maintained therapeutic plasma concen- 
trations. The value of ECs0 in their study was a 
plasma milrinone concentration of 167 ng/ml. 
In conclusion, milrinone is a potent, endothelium- 
independent dilator of the human ITA. With its 
combination of positive inotropic and vasodilator 
activities, it may be beneficial in the perioperative 
treatment of patients undergoing coronary artery 
bypass grafting. This study provides valuable xper- 
imental evidence that milrinone is a prime candidate 
for further clinical testing for this purpose. 
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